Abdominal NeoplasmNCT06614179
A Pan-cancer Screening and Diagnosis Model Based on Abdominal CT Was Established
An observational study of Abdominal Neoplasm, run by Xiangdong Cheng at 2 sites in China.
Trial summary
Abdominal noncontrast scan and contrast-enhanced CT were used to establish a screening and diagnostic model for abdominal tumors Read more about this study
- Who is it for?
- Ages 18 to 75 yearsHealthy volunteers can take part
- Conditions the study is for
- Abdominal Neoplasm
- How many people
- 100,000 participants
- Where
- 2 sitesChina
- Study dates
- 1 Jul 2024to 31 Dec 2029
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 75 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: Patients with abdominal tumors or Non-tumor population
Who may be able to join
- Patients with abdominal tumors:
- all patients were pathologically diagnosed with abdominal tumors;
- The clinical case data of all patients were complete, and complete follow-up was obtained, with clear information on medical visits, operation time and survival status within 2 years. If the cause of death is unknown, it will be recorded as censored data;
- All patients had no history of active abdominal bleeding, no serious infection or other abdominal diseases that affected the observation of CT imaging within 3 months before surgery.
- Non-tumor population:
- all patients have complete clinical case data, complete abdominal CT, no history of malignant tumors, no serious infections or other abdominal diseases that affect the diagnosis and observation of CT imaging.
Who cannot join
- Cases in which contrast-enhanced or noncontrast CT images show unclear lesions, with significant noise and artifacts;
Trial locations and contacts
2 sites in 1 country. Contact the study team or a site near you to ask about taking part.
China2 sites, 2 recruiting
- Recruiting
Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital)
Hangzhou, Zhejiang, 310000
Xiangdong Cheng, PhD., +0086-0571-88128041, chengxd516@126.com
- Recruiting
Zhejiang Cancer Hospital；Cancer hospital of the university of chinese academy of sciences
Hangzhou, Zhejiang, 310022
Pengfei Yu, MD，PhD, +86-571-88128031, ypfzmu@163.com
Xiangdong Cheng, MD，PhD
About this study
Abdominal noncontrast scan and contrast-enhanced CT were used to establish a screening and diagnostic model for abdominal tumors
Read the detailed description
Secondary objective: To establish a grading model of abdominal tumors based on clinical indicators Exploratory Objective: To include CT scans in large-scale non-tumor populations for validation and to improve model accuracy Certainty
- Conditions
- Abdominal Neoplasm
- Medical subject headings
- Abdominal Neoplasms
What is being measured
The primary outcome is the main question the study is designed to answer.
Whether or not there is a diagnosis of abdominal tumor questionnaire
Whether or not there is a diagnosis of abdominal tumor
Measured: first visited at baseline
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted26 Sep 2024
- Study start1 Jul 2024
- Primary completion31 Dec 2029 (estimated)
- Study completion31 Dec 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Abdominal NeoplasmStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Retrospective
- Enrolment
- 100,000 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Xiangdong Cheng
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Xiangdong Cheng, Zhejiang Cancer Hospital
- Investigators
- Xiangdong Cheng, Principal investigator, Zhejiang Cancer Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06614179
- Sponsor's protocol ID
- IIT-2024-279
- Status last verified
- Sep 2024
- First submitted
- 1 Sep 2024
- Last updated
- 26 Sep 2024
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: Abdominal noncontrast scan and contrast-enhanced CT were used to establish a screening and diagnostic model for abdominal tumors
Publications
Hu C, Xia Y, Zheng Z, Cao M, Zheng G, Chen S, Sun J, Chen W, Zheng Q, Pan S, Zhang Y, Chen J, Yu P, Xu J, Xu J, Qiu Z, Lin T, Yun B, Yao J, Guo W, Gao C, Kong X, Chen K, Wen Z, Zhu G, Qiao J, Pan Y, Li H, Gong X, Ye Z, Ao W, Zhang L, Yan X, Tong Y, Yang X, Zheng X, Fan S, Cao J, Yan C, Xie K, Zhang S, Wang Y, Zheng L, Wu Y, Ge Z, Tian X, Zhang X, Wang Y, Zhang R, Wei Y, Zhu W, Zhang J, Qiu H, Su M, Shi L, Xu Z, Zhang L, Cheng X. AI-based large-scale screening of gastric cancer from noncontrast CT imaging. Nat Med. 2025 Sep;31(9):3011-3019. doi: 10.1038/s41591-025-03785-6. Epub 2025 Jun 24.
PubMed 40555751
Study at a glance
From the registry record, last updated by the sponsor on 26 Sep 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Pan-cancer Screening and Diagnosis Model Based on Abdominal CT Was Established
- ClinicalTrials.gov ID
- NCT06614179
- Acronym / sponsor ID
- IIT-2024-279
- Conditions
- Abdominal Neoplasm
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 100,000 participants (estimated)
- Lead sponsor
- Xiangdong ChengUniversity, hospital or other
- Study start
- 1 Jul 2024 (actual)
- Primary completion
- 31 Dec 2029 (estimated)
- Study completion
- 31 Dec 2029 (estimated)
- First posted
- 26 Sep 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Abdominal noncontrast scan and contrast-enhanced CT were used to establish a screening and diagnostic model for abdominal tumors
Detailed description
Secondary objective: To establish a grading model of abdominal tumors based on clinical indicators Exploratory Objective: To include CT scans in large-scale non-tumor populations for validation and to improve model accuracy Certainty
Study design
- Observational model
- Case only
- Time perspective
- Retrospective
Who may qualify
- Ages
- 18 to 75 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- Patients with abdominal tumors or Non-tumor population
Key inclusion criteria (6 listed)
- Patients with abdominal tumors:
- all patients were pathologically diagnosed with abdominal tumors;
- The clinical case data of all patients were complete, and complete follow-up was obtained, with clear information on medical visits, operation time and survival status within 2 years. If the cause of death is unknown, it will be recorded as censored data;
- All patients had no history of active abdominal bleeding, no serious infection or other abdominal diseases that affected the observation of CT imaging within 3 months before surgery.
- Non-tumor population:
Key exclusion criteria (1 listed)
- Cases in which contrast-enhanced or noncontrast CT images show unclear lesions, with significant noise and artifacts;
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Whether or not there is a diagnosis of abdominal tumor questionnaire
Time frame: first visited at baseline
Whether or not there is a diagnosis of abdominal tumor
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 26 Sep 2024.
- Derived from this study: PubMed 40555751Hu C, Xia Y, Zheng Z, Cao M, Zheng G, Chen S, Sun J, Chen W, Zheng Q, Pan S, Zhang Y, Chen J, Yu P, Xu J, Xu J, Qiu Z, Lin T, Yun B, Yao J, Guo W, Gao C, Kong X, Chen K, Wen Z, Zhu G, Qiao J, Pan Y, Li H, Gong X, Ye Z, Ao W, Zhang L, Yan X, Tong Y, Yang X, Zheng X, Fan S, Cao J, Yan C, Xie K, Zhang S, Wang Y, Zheng L, Wu Y, Ge Z, Tian X, Zhang X, Wang Y, Zhang R, Wei Y, Zhu W, Zhang J, Qiu H, Su M, Shi L, Xu Z, Zhang L, Cheng X. AI-based large-scale screening of gastric cancer from noncontrast CT imaging. Nat Med. 2025 Sep;31(9):3011-3019. doi: 10.1038/s41591-025-03785-6. Epub 2025 Jun 24.
- Individual participant dataSharing planned: Yes. Abdominal noncontrast scan and contrast-enhanced CT were used to establish a screening and diagnostic model for abdominal tumors
Related trials for Abdominal Neoplasm
RecruitingPhase 2
Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
Ovarian Cancer, Fallopian Tube Cancer
Not yet recruiting
Nurse-Led Prehabilitation Before Major Abdominal Cancer Surgery
Colorectal Cancer
RecruitingPhase 1
Study of Preoperative Radiation Therapy in Participants With Resectable Recurrent Abdominal Adrenocortical Carcinoma
Adrenocortical Carcinoma (ACC), Recurrent Adrenocortical Carcinoma (ACC)
RecruitingPhase 1
Individual Response to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Treatment of Peritoneal Carcinomatosis From Peritoneal Mesothelioma or Atypical Mesothelial Proliferation or From Ovarian, Colorectal, or Appendiceal Histologies
Peritoneal Mesothelioma, Peritoneal Carcinomatosis
RecruitingPhase 3
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
Ovarian Neoplasms, Fallopian Tube Neoplasms
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Xiangdong Cheng principal investigator
Zhejiang Cancer Hospital
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Abdominal Neoplasm, run by Xiangdong Cheng at 2 sites in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 26 Sep 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Xiangdong Cheng (0086-571-881280, Chengxd516@126.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Whether or not there is a diagnosis of abdominal tumor questionnaire (time frame: first visited at baseline). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06614179, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Sep 2024.